{Reference Type}: Journal Article
{Title}: An updated patent review of stimulator of interferon genes agonists (2021 - present).
{Author}: Xin GF;Chen NN;Li LL;Liu XC;Che CC;Wu BD;You QD;Xu XL;
{Journal}: Expert Opin Ther Pat
{Volume}: 34
{Issue}: 5
{Year}: 2024 May 13
{Factor}: 6.714
{DOI}: 10.1080/13543776.2024.2365409
{Abstract}: <B>UNASSIGNED: </B>Stimulator of Interferon Genes (STING) is an innate immune sensor. Activation of STING triggers a downstream response that results in the expression of proinflammatory cytokines (TNF-α, IL-1β) via nuclear factor kappa-B (NF-κB) or the expression of type I interferons (IFNs) via an interferon regulatory factor 3 (IRF3). IFNs can eventually result in promotion of the adaptive immune response including activation of tumor-specific CD8+ T cells to abolish the tumor. Consequently, activation of STING has been considered as a potential strategy for cancer treatment.<BR><B>UNASSIGNED: </B>This article provides an overview on structures and pharmacological data of CDN-like and non-nucleotide STING agonists acting as anticancer agents (January 2021 to October 2023) from a medicinal chemistry perspective. The data in this review come from EPO, WIPO, RCSB PDB, CDDI.<BR><B>UNASSIGNED: </B>In recent years, several structurally diverse STING agonists have been identified. As an immune enhancer, they are used in the treatment of tumors, which has received extensive attention from scientific community and pharmaceutical companies. Despite the multiple challenges that have appeared, STING agonists may offer opportunities for immunotherapy.